A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE) antibody construct, in patients with refractory solid tumors

Multicentre Phase 1 study of the bispecific EpCAM/CD3 BiTE solitomab in refractory solid tumours.

Publication · 2024-11-06

More detail is on the way.

Full content is being migrated into the new site. Reach out and a senior contact will send you a copy directly.

All white papers, case studies, publications and blogs.

Peer-reviewed and journal articles.

Talk to a senior contact about the work behind this.